Conflict of interest: Nothing to declare.
Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program
Article first published online: 24 JUN 2013
copyright © 2013 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 60, Issue 11, pages 1860–1867, November 2013
How to Cite
Wood, A. C., Maris, J. M., Gorlick, R., Kolb, E. A., Keir, S. T., Reynolds, C. P., Kang, M. H., Wu, J., Kurmasheva, R. T., Whiteman, K., Houghton, P. J. and Smith, M. A. (2013), Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr. Blood Cancer, 60: 1860–1867. doi: 10.1002/pbc.24647
- Issue published online: 11 SEP 2013
- Article first published online: 24 JUN 2013
- Manuscript Accepted: 24 MAY 2013
- Manuscript Received: 8 JAN 2013
- National Cancer Institute. Grant Numbers: NO1-CM-42216, CM91001-03, CA21765, CA108786
- Robert Lutz of ImmunoGen, Inc.
Additional Supporting Information may be found in the online version of this article at the publisher's website.
|pbc24647-sm-0001-SupData-S1.docx||337K||Supplemental Response Definitions.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.